Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, presents a subgroup analysis from the SIMPLIFY-2 study (NCT02101268), comparing momelotinib therapy to standard of care (SoC) treatments in patients with myelofibrosis (MF) and anemia. The analysis highlights the superior and durable efficacy of momelotinib in terms of transfusion-independence rates, symptom control and management of splenomegaly. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть